ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.
ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.
|Data as of
|Data as of
|Summary Toggle Nov 9, 2022 at 8:30 AM EST||
Erytech Pharma 3rd Quarter of 2022 Conference Call and Webcast
|Summary Toggle Nov 8, 2022||
Business Update and Financial Highlights for the Third Quarter of 2022 (after U.S. market close)
|Summary Toggle Sep 13, 2022 at 8:30 AM EDT||
Erytech Pharma 2nd Quarter of 2022 Conference Call and Webcast
RECEIVE E-MAIL ALERTS
Data Provided by Refinitiv. Minimum 15 minutes delayed.